Technimark's Mexicali Facility is Fourth to Earn MedAccred™ Certification
Bolstered by increased investment in additional cleanrooms and increasing the size of the facility,
- Consistent and standardized process
- Subject matter experts on-site
- Greater supply chain visibility
- Ensuring the easy transfer of knowledge to sub-tier suppliers
- Applying industry-accepted and consistent technical requirements to production
In addition to the certification of the facility in
"Obtaining MedAccred and other industry certifications are essential to demonstrate our commitment to excellence," stated Kris Peavy, Chief Commercial Officer, and President of Healthcare at Technimark. "We want our customers to know our commitment is to the highest manufacturing standards in the industry."
Achieving these rigorous standards throughout a thorough and complex audit process demonstrates Technimark's commitment to the continued improvement and enhancement of medical manufacturing. By adhering to the highest manufacturing standards throughout our global facilities, we provide quality and performance assurances for customers and consumers across the world.
About Technimark
Technimark is a global manufacturing solutions provider for the healthcare, consumer packaging, and specialty industrial market. Technimark specializes in precision injection molding, value-added assembly, and full supply chain services. Technimark provides clients with customized, end-to-end solutions based on technology and innovation that improve quality, reduce risk, lower costs, and speed products to market. With facilities in
Media Contact: [email protected]
View original content:https://www.prnewswire.com/news-releases/technimarks-mexicali-facility-is-fourth-to-earn-medaccred-certification-302223021.html
SOURCE Technimark LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RMX Signs Compute Supply Purchase Order with Technologent for NVIDIA H200 GPUs
- Babylist Opens New York Showroom to Bring its Universal Registry to Life
- 2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share